Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds

Mar 16, 2020 | Industry Press Releases

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new data reinforcing the value of Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only FDA-approved reversal agent for the Factor Xa inhibitors rivaroxaban or apixaban.